Global Multiple Myeloma Therapy market likely to propagate by the increase in demand for Multiple Myeloma Therapy for treatment of cancer. Global Multiple Myeloma Therapy market projected to grow with a significant rate during the forecast period, 2020-2027. It is on account of the growing prevalence of blood cancer across the world. Additionally, the growth in the aging population, mounting obese population, increase in healthcare expenditure, and augmented penetration of novel cancer drugs will influence the global multiple myeloma therapy market in the next few years. Multiple myeloma is often convoyed by multiple osteolytic lesions, hypercalcemia, anaemia, and kidney damage.
Moreover, the surge in disposable income and high adoption of the newer therapies would estimate to boost the global Multiple myeloma therapy market in the future periods. Multiple myeloma is caused by malignant proliferation of monoclonal plasma cells, extensive infiltration, and secretion of a large amount of monoclonal immunoglobulin (M protein), which causes extensive bone destruction, repeated infections, anaemia, and hypercalcemia, Hyperviscosity syndrome and renal insufficiency, a series of clinical manifestations of blood system malignant diseases. It is found more common in middle-aged and elderly people.
Furthermore, application of bisphosphonates can reduce skeletal complications, the use of drugs that stimulate blood cell production (growth factors) can increase the number of red blood cells and white blood cells, and the use of better painkillers can also significantly improve quality of life. In addition, the development of newer therapies, including monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors, projected to trigger the global multiple myeloma therapy market in the future time. Moreover, the growing adoption of therapies over traditionally used drugs, including high cell specificity in targeting cancer cells, will boom the global multiple myeloma therapy industry in the forecast period.
Therapy Type Overview in the Global Multiple Myeloma Therapy market
Based on therapy type, the global Multiple Myeloma Therapy market classified into Chemotherapy and Other Drugs (Traditional Chemotherapy, Immunomodulating Agents, Proteasome inhibitors, Histone Deacetylase (HDAC) inhibitors, and Monoclonal Antibodies), Radiation, and Stem Cell Transplant & Other Supportive Treatments. The Chemotherapy and Other Drugs segment will lead the market by 2027 on account of its help to destroy or control cancer cells. Chemotherapy and Other Drugs can be given in a vein or a muscle or taken by mouth after entering in the bloodstream and reach almost all areas of the body.
End-User Overview in the Global Multiple Myeloma Therapy market
Based on end-user, the global Multiple Myeloma Therapy market classified into Hospitals, Clinics, Pharmacy stores, and others. Hospitals segment expected to generate maximum revenue by 2027 due to the increase in the number of aging populations in developing countries along with innovations and advancements in the healthcare industry and financial aids by governments in R&D.
Regional Overview in the Global Multiple Myeloma Therapy market
By geography, the Global Multiple Myeloma Therapy market segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America predicted to generate maximum revenue by 2027, owing to the rising disposables income level, improving health care awareness levels along with the surge in demand for Multiple Myeloma Therapy for the aging population.
Global Multiple Myeloma Therapy market: Competitive Landscape
Companies such as Revlimid, Pomalyst. Janssen Biotech, Inc., Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals, Amgen, Inc., Genzyme Corporation, Juno Therapeutics, Celgene Corporation, Johnson and Johnson, AbbVie Inc., Innate Pharma, and Celldex Therapeutics, Inc are the key players in the Global Multiple Myeloma Therapy Market.
1. Research Strategic Development
1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation
2. Research Methodology
2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation
3. Executive Summary
4. Market Insights
4.1. Economic Factor Analysis
4.1.1. Drivers
4.1.2. Trends
4.1.3. Opportunities
4.1.4. Challenges
4.2. Technological Landscape
4.3. Competitors & Product Analysis
4.4. Regulatory Framework
4.5. Company market share analysis, 2019
4.6. Porter’s Five forces analysis
4.7. New Investment Analysis
4.8. PESTEL Analysis
5. Global Multiple Myeloma Therapy Market Overview
5.1. Market Size & Forecast, 2016-2027
5.1.1. Demand
5.1.1.1. By Value (USD Million)
5.2. Market Share & Forecast, 2016-2027
5.2.1. By Therapy Type
5.2.1.1. Chemotherapy and Other Drugs
5.2.1.1.1. Traditional Chemotherapy
5.2.1.1.2. Immunomodulating Agents
5.2.1.1.3. Proteasome inhibitors
5.2.1.1.4. Histone Deacetylase (HDAC) inhibitors
5.2.1.1.5. Monoclonal Antibodies
5.2.1.2. Radiation
5.2.1.3. Stem Cell Transplant & Other Supportive Treatment
5.2.2. By End-User
5.2.2.1. Hospitals
5.2.2.2. Clinics
5.2.2.3. Others
5.2.3. By Region
5.2.3.1. North America
5.2.3.2. Europe
5.2.3.3. Asia Pacific
5.2.3.4. South America
5.2.3.5. Middle East & Africa
6. North America Multiple Myeloma Therapy Market Overview
6.1. North America Multiple Myeloma Therapy Market Size & Forecast, 2016-2027
6.1.1. Demand
6.1.1.1. By Value (USD Million)
6.2. North America Multiple Myeloma Therapy Market Share & Forecast, 2016-2027
6.2.1. By Therapy Type
6.2.1.1. Chemotherapy and Other Drugs
6.2.1.1.1. Traditional Chemotherapy
6.2.1.1.2. Immunomodulating Agents
6.2.1.1.3. Proteasome inhibitors
6.2.1.1.4. Histone Deacetylase (HDAC) inhibitors
6.2.1.1.5. Monoclonal Antibodies
6.2.1.2. Radiation
6.2.1.3. Stem Cell Transplant & Other Supportive Treatment
6.2.2. By End-User
6.2.2.1. Hospitals
6.2.2.2. Clinics
6.2.2.3. Others
6.2.3. By Country
6.2.3.1. US
6.2.3.2. Canada
6.2.3.3. Mexico
6.2.4. Company Market Share (Top 3-5)
6.2.5. Economic Impact Study on North America Multiple Myeloma Therapy Market
7. Europe Multiple Myeloma Therapy Market Overview
7.1. Europe Multiple Myeloma Therapy Market Size & Forecast, 2016-2027
7.1.1. Demand
7.1.1.1. By Value (USD Million)
7.2. Europe Multiple Myeloma Therapy Market Share & Forecast, 2016-2027
7.2.1. By Therapy Type
7.2.1.1. Chemotherapy and Other Drugs
7.2.1.1.1. Traditional Chemotherapy
7.2.1.1.2. Immunomodulating Agents
7.2.1.1.3. Proteasome inhibitors
7.2.1.1.4. Histone Deacetylase (HDAC) inhibitors
7.2.1.1.5. Monoclonal Antibodies
7.2.1.2. Radiation
7.2.1.3. Stem Cell Transplant & Other Supportive Treatment
7.2.2. By End-User
7.2.2.1. Hospitals
7.2.2.2. Clinics
7.2.2.3. Others
7.2.3. By Country
7.2.3.1. Germany
7.2.3.2. UK
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Rest of Europe
7.2.4. Company Market Share (Top 3-5)
7.2.5. Economic Impact Study on Europe Multiple Myeloma Therapy Market
8. Asia Pacific Multiple Myeloma Therapy Market Overview
8.1. Asia Pacific Multiple Myeloma Therapy Market Size & Forecast, 2016-2027
8.1.1. Demand
8.1.1.1. By Value (USD Million)
8.2. Asia Pacific Multiple Myeloma Therapy Market Share & Forecast, 2016-2027
8.2.1. By Therapy Type
8.2.1.1. Chemotherapy and Other Drugs
8.2.1.1.1. Traditional Chemotherapy
8.2.1.1.2. Immunomodulating Agents
8.2.1.1.3. Proteasome inhibitors
8.2.1.1.4. Histone Deacetylase (HDAC) inhibitors
8.2.1.1.5. Monoclonal Antibodies
8.2.1.2. Radiation
8.2.1.3. Stem Cell Transplant & Other Supportive Treatment
8.2.2. By End-User
8.2.2.1. Hospitals
8.2.2.2. Clinics
8.2.2.3. Others
8.2.3. By Country
8.2.3.1. China
8.2.3.2. India
8.2.3.3. Japan
8.2.3.4. Australia
8.2.3.5. Rest of Asia Pacific
8.2.4. Company Market Share (Top 3-5)
8.2.5. Economic Impact Study on Asia Pacific Multiple Myeloma Therapy Market
9. South America Multiple Myeloma Therapy Market Overview
9.1. South America Multiple Myeloma Therapy Market Size & Forecast, 2016-2027
9.1.1. Demand
9.1.1.1. By Value (USD Million)
9.2. South America Multiple Myeloma Therapy Market Share & Forecast, 2016-2027
9.2.1. By Therapy Type
9.2.1.1. Chemotherapy and Other Drugs
9.2.1.1.1. Traditional Chemotherapy
9.2.1.1.2. Immunomodulating Agents
9.2.1.1.3. Proteasome inhibitors
9.2.1.1.4. Histone Deacetylase (HDAC) inhibitors
9.2.1.1.5. Monoclonal Antibodies
9.2.1.2. Radiation
9.2.1.3. Stem Cell Transplant & Other Supportive Treatment
9.2.2. By End-User
9.2.2.1. Hospitals
9.2.2.2. Clinics
9.2.2.3. Others
9.2.3. By Country
9.2.3.1. Brazil
9.2.3.2. Argentina
9.2.3.3. Rest of South America
9.2.4. Company Market Share (Top 3-5)
9.2.5. Economic Impact Study on South America Multiple Myeloma Therapy Market
10. Middle East & Africa Multiple Myeloma Therapy Market Overview
10.1. Middle East & Africa Multiple Myeloma Therapy Market Size & Forecast, 2016-2027
10.1.1. Demand
10.1.1.1. By Value (USD Million)
10.2. Middle East & Africa Multiple Myeloma Therapy Market Share & Forecast, 2016-2027
10.2.1. By Therapy Type
10.2.1.1. Chemotherapy and Other Drugs
10.2.1.1.1. Traditional Chemotherapy
10.2.1.1.2. Immunomodulating Agents
10.2.1.1.3. Proteasome inhibitors
10.2.1.1.4. Histone Deacetylase (HDAC) inhibitors
10.2.1.1.5. Monoclonal Antibodies
10.2.1.2. Radiation
10.2.1.3. Stem Cell Transplant & Other Supportive Treatment
10.2.2. By End-User
10.2.2.1. Hospitals
10.2.2.2. Clinics
10.2.2.3. Others
10.2.3. By Country
10.2.3.1. Saudi Arabia
10.2.3.2. UAE
10.2.3.3. South Africa
10.2.3.4. Rest of Middle East & Africa
10.2.4. Company Market Share (Top 3-5)
10.2.5. Economic Impact Study on Middle East & Africa Multiple Myeloma Therapy Market
11. Competitor Analysis
11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1. AbbVie, Inc.
11.7.2. Revlimid
11.7.3. Pomalyst
11.7.4. Janssen Biotech, Inc.
11.7.5. Bristol-Myers Squibb Company
11.7.6. Novartis AG
11.7.7. Millennium Pharmaceuticals
11.7.8. Amgen, Inc.
11.7.9. Genzyme Corporation
11.7.10. Juno Therapeutics
11.7.11. Celgene Corporation
11.7.12. Johnson and Johnson
11.7.13. Innate Pharma
11.7.14. Celldex Therapeutics, Inc.
11.7.15. Other Prominent Players